Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, intensifying scrutiny over the safety of its treatments, Bloomberg ...

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.

Biopharma stock Sarepta Therapeutics Inc (NASDAQ:SRPT) is soaring today, up 20.6% at $22.17 at last glance. The biopharmaceutical company announced a strategic restructuring plan, laying off about 500 ...

Shares of drug developer Sarepta Therapeutics surged more than 20% in morning trading, rising after the late-Wednesday news ...

Scott Rubner, Citadel Securities' new head of equity and equity derivatives strategy, expects "robust" retail trading flows ...

Netflix (NASDAQ: NFLX) stock rose 0.9% ahead of the release of the latest earnings report from the streaming giant after the ...

US rare disease meds developer Sarepta Therapeutics late yesterday announced a strategic restructuring plan designed to ...

He's a regular tracker of volatility control funds - "vol control" - or strategies used increasingly by big institutions such as pensions and longer-term endowment funds to keep risk on an even keel.

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

After the market close on Wednesday, Sarepta Therapeutics introduced a strategic restructuring plan that involves focusing on high-value, high-impact programs and supporting long-term financials.

U.S. stock futures were mixed early Thursday morning after President Trump dismissed rumors of plans to remove Fed Chair ...